Singapore-listed Cordlife Group has revised its offer price to acquire all the remaining stake in Malaysia’s cord blood banking firm StemLife Bhd from 54 sen to 57.5 sen per share after it hit the 90 per cent stake ownership mark this week that triggered an unconditional takeover bid.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
